0000950170-23-002622.txt : 20230213 0000950170-23-002622.hdr.sgml : 20230213 20230213163057 ACCESSION NUMBER: 0000950170-23-002622 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230210 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 23618993 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 abio-20230210.htm 8-K 8-K
0000907654false00009076542023-02-102023-02-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2023 (February 10, 2023)

 

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10170 Church Ranch Way

Suite 100

 

Westminster, Colorado

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

ABIO

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

ARCA biopharma, Inc. (“ARCA” or the "Company") and Christopher D. Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA have mutually agreed to conclude Mr. Ozeroff’s employment effective March 31, 2023. Mr. Ozeroff's departure is not the result of any disagreement with ARCA on any matter relating to its operations, policies or practices, or regarding the general direction of the company.

 

Pursuant to Mr. Ozeroff's existing employment agreement, as previously amended, ARCA will provide Mr. Ozeroff severance benefits pursuant to the terms of his existing employment agreement with the Company, as previously amended. The severance benefits include severance payments and reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). The severance benefits are conditioned on the execution by Mr. Ozeroff of a legal release of claims.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit Number

 

Description

 

 

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCA biopharma, Inc.
(Registrant)

 

 

 

 

Date:

February 13, 2023

By:

/s/ C. Jeffrey Dekker

 

 

 

Name: C. Jeffrey Dekker
Title: Chief Financial Officer

 

 EX-101.SCH 2 abio-20230210.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 abio-20230210_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 abio-20230210_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Feb. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 10, 2023
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity Emerging Growth Company false
Securities Act File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code (720)
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
XML 6 abio-20230210_htm.xml IDEA: XBRL DOCUMENT 0000907654 2023-02-10 2023-02-10 0000907654 false 8-K 2023-02-10 ARCA biopharma, Inc. DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 (720) 940-2200 false false false false Common ABIO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports abio-20230210.htm abio-20230210.xsd abio-20230210_lab.xml abio-20230210_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abio-20230210.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "abio-20230210.htm" ] }, "labelLink": { "local": [ "abio-20230210_lab.xml" ] }, "presentationLink": { "local": [ "abio-20230210_pre.xml" ] }, "schema": { "local": [ "abio-20230210.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abio", "nsuri": "http://www.arcabiopharma.com/20230210", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "abio-20230210.htm", "contextRef": "C_eab76688-ece6-4c2d-8c94-abe6fc901193", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "abio-20230210.htm", "contextRef": "C_eab76688-ece6-4c2d-8c94-abe6fc901193", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.arcabiopharma.com/20230210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-002622-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-002622-xbrl.zip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�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end